Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 225

Schrödinger shuts IPO at $232m

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Feb 11, 2020

Iora Health ignites $126m round

Cox Enterprises formed part of a consortium that provided $126m for Iora Health, a healthcare provider whose investors also include Humana and General Electric.

Feb 11, 2020

Stilla stacks up series B funding

Illumina Ventures returned to reinvest in a $21.8m round for the DNA-analysis system developer having led its series A round in 2018.

Feb 11, 2020

Sonoma sends for Lyell in $40m series A

Sonoma Biotherapeutics has emerged from stealth with $40m from investors including Lyell Immunopharma and is developing regulatory T-cell therapies for autoimmune and degenerative diseases.

Feb 10, 2020

MaaT meets investors for series B funding

Biocodex returned for a $19.8m round that boosted microbiome drug developer MaaT Pharma's overall funding to more than $33m.

Feb 10, 2020

Corporate venturing deal net: 3-7 February 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Feb 7, 2020

Schrödinger shakes out $202m from IPO

The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.

Feb 7, 2020

Lunaphore loops in series C funding

The tissue analysis technology developer has now raised more than $37m, having received $23.6m in a first tranche of its series C round that was led by PHC Holdings.

Feb 7, 2020

Vineti salutes Cardinal in $35m series C

The personalised therapy management platform closed a round led by Cardinal Health with backing from Novartis and Kite Pharma, taking its overall funding to more than $82m.

Feb 7, 2020

Beam Therapeutics shines in $180m IPO

Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.

Feb 6, 2020

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here